PDS Biotechnology (PDSB) Preferred Stock Liabilities (2014 - 2015)
PDS Biotechnology's (PDSB) quarterly Preferred Stock Liabilities came in at $477191.0 in Q3 2015, down 97.33% on a QoQ basis from $17.9 million in Q4 2014.
PDS Biotechnology (PDSB) Preferred Stock Liabilities (2014 - 2015) Analysis & Trends
PDS Biotechnology (PDSB) has 2 years of Preferred Stock Liabilities data on file, last reported at $477191.0 in Q3 2015.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $477191.0 in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $477191.0 (changed N/A YoY) and the FY2014 annual result came in at $17.9 million, up 8.81% from the prior year.
- Preferred Stock Liabilities eased to $477191.0 in Q3 2015, from $17.9 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $17.9 million in Q4 2014 to a low of $477191.0 in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2015 | 477,191.00 |
| Dec 31, 2014 | 17.86 Mn |